Get the Stockscreener App
43.70
4.07%
1.71
Pre-market:
44.51
0.81
+1.85%
Vaxcyte Inc stock is traded at $43.70, with a volume of 3.02M.
It is up +4.07% in the last 24 hours and up +36.56% over the past month.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.
See More
Previous Close:
$41.99
Open:
$42.12
24h Volume:
3.02M
Relative Volume:
1.87
Market Cap:
$5.67B
Revenue:
-
Net Income/Loss:
$-507.65M
P/E Ratio:
-9.50
EPS:
-4.6
Net Cash Flow:
$-616.24M
1W Performance:
+2.44%
1M Performance:
+36.56%
6M Performance:
+55.85%
1Y Performance:
-60.84%
1-Day Range:
$41.29
$44.02
1-Week Range:
$40.35
$44.02
52-Week Range:
$27.66
$118.62
Vaxcyte Inc Stock (PCVX) Company Profile
Name
Vaxcyte Inc
Sector
Industry
Phone
650-837-0111
Address
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Compare PCVX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
43.70 | 5.45B | 0 | -507.65M | -616.24M | -4.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-12-25 | Initiated | Goldman | Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-20-24 | Initiated | Goldman | Buy |
| Dec-07-23 | Initiated | Mizuho | Buy |
| Apr-18-23 | Initiated | TD Cowen | Outperform |
| Jan-03-23 | Reiterated | Needham | Buy |
| Dec-15-22 | Initiated | Guggenheim | Buy |
| Nov-17-22 | Initiated | BTIG Research | Buy |
| Dec-29-21 | Resumed | Jefferies | Buy |
| Jun-24-21 | Resumed | Jefferies | Buy |
| Jul-07-20 | Initiated | BofA Securities | Buy |
| Jul-07-20 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-07-20 | Initiated | Needham | Buy |
View All
Vaxcyte Inc Stock (PCVX) Latest News
Analyzing net buyer seller activity in Vaxcyte Inc.Global Markets & AI Driven Price Predictions - newser.com
What high frequency data says about Vaxcyte Inc.July 2025 EndofMonth & Reliable Price Breakout Alerts - newser.com
Applying sector rotation models to Vaxcyte Inc.Earnings Recap Summary & Reliable Price Action Trade Plans - newser.com
Can Vaxcyte Inc. (5VA) stock sustain double digit ROE2025 Market Overview & Daily Risk Controlled Trade Plans - newser.com
Vaxcyte (NASDAQ:PCVX) Shares Up 4.6%Time to Buy? - MarketBeat
Is Vaxcyte Inc a good long term investmentExit Strategy Tips & Turn Market Volatility into Wealth - earlytimes.in
Is Vaxcyte Inc. (5VA) stock cheap by valuation metricsQuarterly Earnings Report & Low Risk High Reward Trade Ideas - newser.com
Will Vaxcyte Inc. see short term momentumMarket Activity Report & Daily Profit Maximizing Trade Tips - newser.com
Why Vaxcyte Inc. (5VA) stock is a strong analyst pickJuly 2025 Setups & AI Enhanced Trading Signals - newser.com
Thermo Fisher Scientific’s Valuation: Assessing the Impact of Its $1 Billion Vaxcyte Vaccine Manufacturing Deal - Yahoo Finance
Bank of America Securities Maintains a Buy Rating on Vaxcyte (PCVX) - Yahoo Finance
What consensus target says about Vaxcyte Inc. (5VA) stockBuy Signal & Free Weekly Chart Analysis and Trade Guides - newser.com
Will Vaxcyte Inc. (5VA) stock sustain dividend payouts2025 Retail Activity & Safe Entry Point Alerts - newser.com
111 Capital Takes Position in Vaxcyte, Inc. $PCVX - MarketBeat
PCVX Stock Price and Chart — NASDAQ:PCVX - TradingView
Will breakout in Vaxcyte Inc. lead to full recoveryExit Point & Reliable Price Breakout Alerts - newser.com
Is Vaxcyte Inc. (5VA) stock attractive post correctionJuly 2025 Market Mood & Risk Controlled Daily Trade Plans - newser.com
What candlestick patterns are forming on Vaxcyte Inc.2025 Macro Impact & Free Daily Entry Point Trade Alerts - newser.com
Vaxcyte’s Strategic Moves: Impact on PCVX - StocksToTrade
BofA Securities Maintains Vaxcyte(PCVX.US) With Buy Rating, Cuts Target Price to $134 - 富途牛牛
Why Vaxcyte Inc. stock is in analyst buy zoneWeekly Earnings Recap & Safe Entry Point Identification - newser.com
Earnings visualization tools for Vaxcyte Inc.Swing Trade & AI Driven Stock Price Forecasts - newser.com
A Look at Vaxcyte’s (PCVX) Valuation Following $1 Billion Thermo Fisher Manufacturing Deal - simplywall.st
Vaxcyte Inc.’s volatility index tracking explainedWeekly Trend Summary & High Return Trade Opportunity Guides - newser.com
Is Vaxcyte Inc. (5VA) stock a buy before earnings results2025 Historical Comparison & Growth Oriented Trade Recommendations - newser.com
Vaxcyte teams up with Thermo Fisher to ensure future vaccine production - MSN
What analysts say about Vaxcyte Inc 5VA stockMarket Rumors and News & Collaborate and Win Together - earlytimes.in
Thermo Fisher Launches Four-Part Bond Offering Ahead Of Possible Government Shutdown - Sahm
Vaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services - Sahm
Vaxcyte signs $1 billion manufacturing deal with Thermo Fisher By Investing.com - Investing.com Nigeria
Vaxcyte, Inc. to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services - MarketScreener
What Does Wall Street Think About Vaxcyte (PCVX)? - MSN
Vaxcyte Signs 15-Year Agreement with Patheon - TipRanks
Vaxcyte to Establish Fill-Finish Manufacturing in North - GlobeNewswire
Thermo Fisher Launches Four-Part Bond Offering Ahead Of Possible Government Shutdown - Benzinga
Vaxcyte to Expand Fill-Finish Manufacturing Capacity in US; Shares Up Pre-Bell - MarketScreener
Vaxcyte Inc Stock (PCVX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Vaxcyte Inc Stock (PCVX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| GUGGENHIME ANDREW | PRESIDENT AND CFO |
Apr 07 '25 |
Option Exercise |
20.93 |
4,777 |
99,983 |
131,950 |
| PICKERING GRANT | CHIEF EXECUTIVE OFFICER |
Apr 04 '25 |
Option Exercise |
8.96 |
20,533 |
183,888 |
518,775 |
| Eydelman Mikhail | SVP, GEN COUNSEL & CORP SEC |
Mar 05 '25 |
Option Exercise |
21.41 |
5,000 |
107,050 |
46,620 |
| Eydelman Mikhail | SVP, GEN COUNSEL & CORP SEC |
Mar 05 '25 |
Sale |
70.74 |
5,000 |
353,699 |
41,620 |
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):